All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 650+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Johnson & Johnson, Astellas, Ipsen all get EU adcomm (CHMP) thumbs up
Small molecule, pulmonary arterial hypertension, liver disease, monoclonal antibody, adenocarcinoma, cancer - Read more

AbbVie snags EC (Europe) approval for fourth Skyrizi indication
Monoclonal antibody, ulcerative colitis - Read more

Sun Pharma basks in the glow of an FDA approval for their alopecia hair loss med
Small molecule, alopecia areata - Read more

CStone Pharmaceuticals lands EC approval for lung cancer antibody
Monoclonal antibody, non-small cell lung cancer - Read more

THE GOOD
Clinical Trials

Calliditas Therapeutics doesn’t get stiffed by their Ph2b clinical trial, meets primary endpoint
Small molecule, primary biliary cholangitis, liver stiffness - Read more

CEL-SCI unbiased with their post-Ph3 bias analysis
Cancer vaccine, neoadjuvant (pre-surgery) immunotherapy, head & neck cancer - Read more

THE GOOD
Earnings & Finances

Bristol Myers Squibb ended the week on a high-note; stronger than expected earnings sent stock up 9% - Read more

THE GOOD
Fundraises

Confo Therapeutics €60M ($65M) Series B
Small molecule, antibody, drug discovery - Read more

ReviR Therapeutics $30M Series A
Small molecule, Huntington's disease, Charcot-Marie-Tooth disease, amyotrophic lateral sclerosis - Read more

ProMIS Neuroscience $122.7M private placement
Antibody, Alzheimer’s disease, amyotrophic lateral sclerosis, multiple system atrophy - Read more

THE GOOD
Partnerships

Eisai, Medidata partner on clinical trial data studio
Clinical trial management, data studio - Read more

Innovent Biologics, WeComput AI-driven drug discovery partnership
AI, drug discovery & development, R&D - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Approvals & Labels

EMA adcomm not impressed enough by Biogen, Eisai’s Leqembi to give their recommendation
Monoclonal antibody, Alzheimer’s disease - Read more

THE BAD
Clinical Trials

Bristol Myers Squibb does about-face, halts multiple myeloma program months after filing for Ph3
Bispecific antibody, multiple myeloma, cancer - Read more

Acticor Pharma discontinues Ph2/3 blood thinner trial after futility analysis
Antibody fragment, adjunct therapy, blood thinner, stroke - Read more

THE BAD
Earnings & Finances

Dexcom stock shatters after lowering 2024 sales forecast
Medical device, continuous glucose monitoring, diabetes - Read more

THE BAD
Lawsuits

Pfizer, BioNTech call GSK COVID-19 patent suit “unenforceable”
Covid-19 vaccine, drug patent - Read more [Paywall]

THE BAD
Layoffs

Cue Biopharma cuts 25% of staff, seeks partnerships to further oncology pipeline
Fusion protein, HPV, carcinoma, cancer - Read more

THE UGLY
Patient Access

FDA warns of dosing errors in compounded semaglutide products
GLP-1, obesity, diabetes - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.